Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | LPL | P06858 | 9/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16922341 | 0.86 | LPL (0.49) | ESR2LPLLIPGLMNA | |
| SCHEMBL2354573 | 0.86 | LPL (0.49) | ALDH1A1KDM4EGAAMAPTKMT2A | |
| SCHEMBL15375421 | 0.86 | ALDH1A1 (0.44) | ALDH1A1KDM4EGAAMAPTPTK2B | |
| SCHEMBL628026 | 0.85 | JAK3 (0.53) | GAAMAPTKMT2A | |
| SCHEMBL20644595 | 0.85 | MAPT (0.51) | ALDH1A1KDM4EGAAMAPTPTK2B | |
| SCHEMBL20644510 | 0.85 | LPL (0.65) | ALDH1A1KDM4EMAPTGFERKMT2A | |
| SCHEMBL15788150 | 0.85 | LPL (0.45) | KMT2AESR2LPLLIPG | |
| SCHEMBL539141 | 0.85 | LPL (0.47) | ALDH1A1KDM4EGAAMAPTKMT2A | |
| SCHEMBL138606 | 0.85 | LPL (0.47) | ALDH1A1KDM4EMAPTKMT2ALPL | |
| SCHEMBL16685004 | 0.83 | LPL (0.46) | ESR2LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 465 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466889-A | 1H-pyrrole [2,3-b ] pyridine compound and synthetic method and application thereof | 杭州医学院 | 2024-01-30 | — | — | CN | claimed |
| US-12534463-B2 | Substituted tricyclic compounds as FGFR inhibitors | INCYTE CORPORATION (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4674852-A1 | PREPARATION METHOD FOR AND USE OF DIHYDROTHIENOPYRIMIDINE DERIVATIVE | Innovstone Therapeutics Limited (CN) | 2026-01-07 | — | — | EP | disclosed |
| US-12516059-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250388573-A1 | FUSED BICYCLIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250382277-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | UNIV ARIZONA (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250352550-A1 | SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE | UNIV MASARYKOVA (CZ) | 2025-11-20 | — | — | US | disclosed |
| EP-4648765-A1 | MUTANT-SELECTIVE EGFR INHIBITORS | Dana-Farber Cancer Institute, Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-4602046-A1 | SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE | Masarykova Univerzita (CZ) | 2025-08-20 | — | — | EP | disclosed |
| WO-2008148867-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| EP-1996594-A2 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | US | disclosed |
| WO-2008088881-A1 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008073785-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007109093-A2 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | WYETH (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219186-A1 | Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| US-20060241106-A1 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
| EP-1611112-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | Vernalis (Cambridge) Limited (GB) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004072051-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534463-B2 | Substituted tricyclic compounds as FGFR inhibitors | FGFR3, FGFR1, FGFR4 | ALDH1A1 2330/4885KDM4E 756/4885GAA 2000/4885 |
| US-20250388573-A1 | FUSED BICYCLIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | ALDH1A1 3975/4885KDM4E 1871/4885GAA 3562/4885 |
| US-20250382277-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK3, CLK1 | ALDH1A1 4568/4885KDM4E 3764/4885GAA 2684/4885 |
| US-20250352550-A1 | SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE | FLT3, ROS1, MAP4K2 | ALDH1A1 2094/4885KDM4E 814/4885GAA 3033/4885 |
| US-20060241106-A1 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 380/4885KDM4E 4409/4885GAA 3531/4885 |
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | ALDH1A1 4026/4885KDM4E 3769/4885GAA 1977/4885 |
| US-20070219186-A1 | Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof | DPYD, TYMP, TYMS | ALDH1A1 253/4885KDM4E 2898/4885GAA 2845/4885 |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3C2B, PIK3C2A, PIK3R1 | ALDH1A1 4070/4885KDM4E 3811/4885GAA 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.